07:16 AM EDT, 06/05/2024 (MT Newswires) -- Vir Biotechnology ( VIR ) said Wednesday that preliminary data from a mid-stage trial evaluating its investigational hepatitis therapies tobevibart and elebsiran showed sustained virologic response from the two drugs, suggesting potential efficacy.

All six patients of the study achieved clinically significant responses to the hepatitis delta virus, with half of the participants achieving a certain normalization required for hepatitis treatment, Vir said.

The preliminary data shows 12 weeks of treatment with either tobevibart and elebsira, the company said.

Vir said it plans to report additional 24-week data for all 60 participants in Q4.

Price: 11.48, Change: +0.90, Percent Change: +8.51